Understanding how a gene variant called FOG2S657G contributes to Coronary Microvascular Disease
Friend of GATA 2 (FOG2) S657G regulates ß1-adrenergic receptor and cardiac work to promote Coronary Microvascular Disease
This project explores how a specific gene change, FOG2S657G, might lead to Coronary Microvascular Disease by affecting heart function.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11141810 on NIH RePORTER |
What this research studies
Coronary Microvascular Disease (CMVD) is a common heart condition causing chest pain and other serious issues, yet we don't have targeted treatments for it. Our team previously found a specific gene change, called FOG2S657G, that is linked to CMVD. Early findings suggest that this gene change causes an increase in a protein called the β1-adrenergic receptor, which plays a role in how hard your heart works. We believe this increased heart activity creates a mismatch between the heart's blood supply and its oxygen needs, contributing to CMVD. This work aims to gather more information on how this gene change leads to CMVD, paving the way for future treatment options.
Who could benefit from this research
Good fit: Patients who have Coronary Microvascular Disease or are at risk due to the FOG2S657G gene variant could potentially benefit from future treatments developed from this research.
Not a fit: Patients whose heart conditions are not related to Coronary Microvascular Disease or this specific genetic variant may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent or treat Coronary Microvascular Disease by targeting the specific gene and protein involved.
How similar studies have performed: This research builds upon prior findings that identified a specific gene variant associated with Coronary Microvascular Disease and its effect on heart proteins.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Guerraty, Marie a — University of Pennsylvania
- Study coordinator: Guerraty, Marie a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.